Olaparib, a potent PARP inhibitor primarily marketed under the brand name Lynparza, has revolutionized the treatment of BRCA-mutated cancers, including ovarian, breast, pancreatic, and prostate cancers. As the global demand for targeted therapies surges, identifying a reliable Olaparib Global Buyers List has become a priority for API manufacturers and pharmaceutical distributors worldwide. In this guide, we explore the landscape of Olaparib procurement, the types of entities driving demand, and how to navigate the complexities of the global pharmaceutical supply chain. Understanding the Global Demand for Olaparib The market for Olaparib is driven by its expanding clinical indications. As healthcare systems shift toward personalized medicine, the volume of procurement for this active pharmaceutical ingredient…